Literature DB >> 9061812

Presynaptic dopaminergic function in the striatum of schizophrenic patients.

M H Dao-Castellana1, M L Paillère-Martinot, P Hantraye, D Attar-Lévy, P Rémy, C Crouzel, E Artiges, A Féline, A Syrota, J L Martinot.   

Abstract

The dopaminergic hypothesis of schizophrenia postulates increased brain dopaminergic activity. Two previous studies reported increased 18F-DOPA uptake with positron emission tomography in schizophrenic patients (n = 5, n = 7). In the present study, striatal dopaminergic function was assessed in vivo in six untreated schizophrenics and seven control subjects, comparable for age and sex. The 18F-fluoro-L-DOPA (18F-DOPA) uptake rate constant Ki was determined in the caudate and putamen using coregistered positron emission tomography and magnetic resonance imaging. No difference between groups for mean Ki was found. The variability of the 18F-DOPA uptake values was higher in the caudate (p < 0.01) and in the putamen (p < 0.001) in schizophrenic patients than in control subjects, suggesting that schizophrenia is a disorder involving heterogeneous states of the striatal presynaptic dopaminergic function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061812     DOI: 10.1016/S0920-9964(96)00102-8

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  34 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

Review 3.  The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.

Authors:  John H Krystal; D Cyril D'Souza; Jürgen Gallinat; Naomi Driesen; Anissa Abi-Dargham; Ismene Petrakis; Andreas Heinz; Godfrey Pearlson
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

5.  Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.

Authors:  G J E Schmitt; T Frodl; S Dresel; C la Fougère; R Bottlender; N Koutsouleris; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-15       Impact factor: 5.270

Review 6.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 7.  Executive function, neural circuitry, and genetic mechanisms in schizophrenia.

Authors:  Daniel Paul Eisenberg; Karen Faith Berman
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

8.  Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia.

Authors:  Meredith A Reid; Nina V Kraguljac; Kathy B Avsar; David M White; Jan A den Hollander; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2013-05-21       Impact factor: 4.939

Review 9.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

Review 10.  Dopamine hypothesis of schizophrenia: making sense of it all.

Authors:  Mitsuru Toda; Anissa Abi-Dargham
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.